Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ischemia/Reperfusion Injury Clear all
Completed No phase listed Observational

MRI of Myocardial Infarction

NCT03531151
View directory record Official record
Conditions
Myocardial Infarction, Myocardial Ischemia, Myocardial Injury, Myocardial Fibrosis, Myocardial Reperfusion Injury, Myocardial Edema, Myocardial Necrosis, Heart Failure, Ischemic Heart Disease, Ischemic Cardiomyopathy, Hemorrhage
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

NCT00995670
View directory record Official record
Conditions
Hyperglycemia
Interventions
5% dextrose, Vitamin C, Simvastatin, Sevoflurane
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 30, 2026, 4:45 AM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

NCT04531592
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic acid, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Denver, Colorado • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 2Phase 3 Interventional

Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery

NCT00226369
View directory record Official record
Conditions
Congenital Heart Defects
Interventions
CY-1503
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 45 Days
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 30, 2026, 4:45 AM EDT
Not yet recruiting Phase 3 Interventional

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

NCT03176186
View directory record Official record
Conditions
Post-Cardiac Arrest Syndrome
Interventions
Xenon
Combination Product
Lead sponsor
Invero Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Hartford, Connecticut • Gainesville, Florida • Gulfport, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 30, 2026, 4:45 AM EDT
Suspended Phase 1 Interventional

Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction

NCT00846378
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Post conditioning, Usual Care for STEMI
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 30, 2026, 4:45 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

NCT01884038
View directory record Official record
Conditions
Liver Transplant
Interventions
treprostinil sodium, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation

NCT00582010
View directory record Official record
Conditions
Reperfusion Injury, Liver Injury
Interventions
inhaled nitric oxide, nitrogen gas
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 30, 2026, 4:45 AM EDT
Active, not recruiting No phase listed Observational

Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation

NCT00457847
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 65 Years
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Recruiting No phase listed Observational

Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation

NCT00552357
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years to 68 Years
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

NCT01572909
View directory record Official record
Conditions
Reperfusion Injury, STEMI
Interventions
Bendavia (MTP-131), Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Port Orange, Florida • Detroit, Michigan • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 30, 2026, 4:45 AM EDT
Completed No phase listed Observational Results available

Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19

NCT04397939
View directory record Official record
Conditions
COVID-19, Myocardial Reperfusion Injury, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
4,695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 30, 2026, 4:45 AM EDT
Withdrawn Phase 3 Interventional

Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation

NCT00592306
View directory record Official record
Conditions
Lung Transplant
Interventions
thymoglobulin (intraoperative), thymoglobulin (postoperative)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Results available

Reoxygenation After Cardiac Arrest II (REOX II Study)

NCT02698826
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Protocol for rapid FiO2 optimization
Other
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Sodium Nitrite in Acute Myocardial Infarction

NCT00924118
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Sodium Nitrite
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Baltimore, Maryland • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 30, 2026, 4:45 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

NCT06853223
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Recruiting Not applicable Interventional

Transplantation of Autologously Derived Mitochondria Following Ischemia

NCT02851758
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication
Interventions
autologous mitochondria transplantation
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 1 Interventional

Management of Compartment Syndrome With Ultrafiltration

NCT00022815
View directory record Official record
Conditions
Compartment Syndrome
Interventions
Tissue ultrafiltration
Device
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
14 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2008 · Synced Oct 30, 2026, 4:45 AM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

NCT04531579
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic Acid Solution, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 30, 2026, 4:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

NCT04005469
View directory record Official record
Conditions
Ischemia Reperfusion Injury, Delayed Graft Function
Interventions
Treprostinil
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts

NCT01172691
View directory record Official record
Conditions
Liver Transplant
Interventions
Inhaled Nitric Oxide (iNO), Placebo Arm (Nitrogen)
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
17 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 4 Interventional Results available

Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients

NCT01167569
View directory record Official record
Conditions
Reperfusion Injury
Interventions
Ascorbic Acid, 5 % Dextrose Water or Normal Saline
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass

NCT02151877
View directory record Official record
Conditions
Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery, Inflammatory Reaction After Neonatal Cardiac Surgery
Interventions
Inhaled Nitric Oxide, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
1 Day to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Not applicable Interventional

N-acetylcysteine in Liver Transplantation

NCT00736541
View directory record Official record
Conditions
End Stage Liver Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
Ibtesam Hilmi
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 30, 2026, 4:45 AM EDT